ArticleJMIR research protocols2026
Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer treatment increasingly emphasizes quality-of-life maintenance alongside oncological control. Integrative Traditional East Asian Medicine (TEAM), including traditional Chinese medicine, traditional Korean medicine, and Kampo medicine, has been used as an adjunctive approach for symptom management during cancer treatment. However, evidence regarding its effectiveness and safety across different disease stages remains heterogeneous and has not been comprehensively synthesized.
objectiveThis systematic review and meta-analysis aims to evaluate the clinical effectiveness, safety, and quality-of-life benefits of TEAM-based adjunctive therapies combined with standard conventional treatments in patients with prostate cancer.
methodsRandomized controlled trials will be identified through comprehensive multilingual searches of PubMed, Embase, China National Knowledge Infrastructure, Oriental Medicine Advanced Searching Integrated System, Research Information Sharing Service, and other databases from inception to January 2026. Two reviewers will independently screen studies, extract data, and assess risk of bias using the Cochrane risk of bias 2 tool. Primary outcomes will consist of tumor-related outcomes (prostate-specific antigen levels and Response Evaluation Criteria in Solid Tumors-evaluated tumor response rates) and survival outcomes (overall survival and progression-free survival). Secondary outcomes will include clinical symptoms (International Prostate Symptom Score), pain scores (visual analog scale or numeric rating scale), quality of life, and treatment-related adverse events. Potential herb-drug interactions reported in primary trials will also be systematically assessed. Meta-analyses will be performed using random effects models in RevMan (version 5.4). In cases of substantial heterogeneity (I²≥50%), sensitivity and subgroup analyses will be conducted. The certainty of evidence will be assessed with the Grading of Recommendations Assessment, Development, and Evaluation approach.
resultsThe study selection process will be illustrated using a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. Where appropriate, pooled effect estimates will be presented using forest plots.
conclusionsThis review will provide comprehensive evidence on the role of TEAM-based adjunctive therapies in prostate cancer care across disease stages and will inform the development of integrative oncology guidelines.
trial registrationPROSPERO CRD420251275137; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251275137. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/94053.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.